Israeli - Kiingereza - Ministry of Health

novartis israel ltd - omalizumab - powder and solvent for solution for injection - omalizumab 150 mg/dose - omalizumab - omalizumab - allergic asthma xolair is indicated for patients 6 to 12 years of age with severe persistent asthma and for patients 12 years of age and older with moderate to severe persistent asthma, who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. limitations of use: xolair is not indicated for the relief of acute bronchospasm or status asthmaticus. xolair is not indicated for the treatment of other allergic conditions.chronic rhinosinusitis with nasal polyps (crswnp) xolair is indicated as an add-on therapy with intranasal corticosteroids (inc) for the treatment of adults (18 years and above) with severe crswnp for whom therapy with inc does not provide adequate disease control.chronic spontaneous urticaria (csu) xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to h1 antihistamine treatment.

Filipino - Kiingereza - FDA (Food And Drug Administration)

novartis healthcare phils inc - artemether , lumfantrine - tablet - 20mg / 120mg

Filipino - Kiingereza - FDA (Food And Drug Administration)

novartis healthcare phils inc - crotamiton - cream, topical - 10g/100g (10%)

Filipino - Kiingereza - FDA (Food And Drug Administration)

novartis healthcare phils inc - hydroxyethylrutoside - tablet, sugar coated - 200 mg

Filipino - Kiingereza - FDA (Food And Drug Administration)

novartis healthcare phils inc - pizotifen , thiamine hcl , riboflavin phosphate , pyridoxine hcl , nicotinamide - capsule - 500mcg + 3.00mg + 3.20mg + 2.40mg + 19.00mg

Filipino - Kiingereza - FDA (Food And Drug Administration)

novartis healthcare phils inc - pizotifen , vitamin b complex (complete formulation on reverse side) - syrup

Filipino - Kiingereza - FDA (Food And Drug Administration)

novartis healthcare phils inc - tribenoside , lidocaine hydrochloride - cream, topical - 5 1g+2 1g

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; iron oxide yellow; titanium dioxide; hypromellose; purified talc; macrogol 4000 - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - inclisiran sodium -

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - inclisiran sodium -